IOVANCE BIOTHERAPEUTICS, INC. 8K

The 8-K reports that Iovance Biotherapeutics furnished an updated corporate overview presentation detailing its Amtagvi commercialization, TIL therapy pipeline, and financial outlook, including Q2 2026 results and cash runway into 2H 2028.

Iovance Biotherapeutics, Inc. furnished an investor corporate overview presentation as an Exhibit 99.1 to its Form 8-K, providing updated information on its commercial progress with Amtagvi for advanced melanoma, global treatment center footprint and payer coverage, development pipeline across multiple solid tumor indications (including NSCLC, soft tissue sarcomas, and endometrial cancer), next‑generation TIL and IL‑2/IL‑12 programs, key ongoing and planned registrational trials, and a financial update indicating approximately $99 million in second quarter 2026 revenue, 56% gross margin (excluding D&A), and a cash balance of about $304 million with expected runway into the second half of 2028.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

8K

Source Type

fda

Accession

0001104659-26-092145

Alert Tier

5